See more : Deutsche Bank Aktiengesellschaft (DB) Income Statement Analysis – Financial Results
Complete financial analysis of Quoin Pharmaceuticals, Ltd. (QNRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quoin Pharmaceuticals, Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- JW Pharmaceutical Corporation (001065.KS) Income Statement Analysis – Financial Results
- Saul Centers, Inc. (BFS) Income Statement Analysis – Financial Results
- B. Riley Financial, Inc. – 6.37 (RILYM) Income Statement Analysis – Financial Results
- Chang Jiang Shipping Group Phoenix Co.,Ltd (000520.SZ) Income Statement Analysis – Financial Results
- HSBC Holdings plc (HBCYF) Income Statement Analysis – Financial Results
Quoin Pharmaceuticals, Ltd. (QNRX)
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -280.00K | 0.00 | -280.00K | 0.00 |
| Cost of Revenue | 103.44K | 103.64K | 104.12K | 104.77K | 227.06K | 125.72K | 104.22K | 89.13K | 18.27K |
| Gross Profit | -103.44K | -103.64K | -104.12K | -104.77K | -227.06K | -405.72K | -104.22K | -369.13K | -18.27K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 144.90% | 0.00% | 131.83% | 0.00% |
| Research & Development | 3.31M | 2.67M | 1.56M | 244.16K | 45.65K | 8.26M | 5.89M | 8.26M | 1.52M |
| General & Administrative | 6.07M | 6.58M | 4.50M | 1.43M | 1.51M | 7.97M | 4.20M | 7.97M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.07M | 6.58M | 4.50M | 1.43M | 1.51M | 7.97M | 4.20M | 7.97M | 1.06M |
| Other Expenses | 0.00 | 417.31K | -14.03M | -378.33K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.38M | 9.26M | 6.06M | 1.67M | 1.56M | 16.22M | 10.10M | 16.22M | 2.58M |
| Cost & Expenses | 9.38M | 9.26M | 6.06M | 1.67M | 1.56M | 16.22M | 10.10M | 16.22M | 2.60M |
| Interest Income | 692.82K | 95.75K | 1.37K | 47.02 | 0.00 | 0.00 | 0.00 | 0.00 | 1.03K |
| Interest Expense | 0.00 | 714.08K | 1.09M | 47.02K | 412.29K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 103.44K | 103.64K | 104.12K | 104.77K | 227.06K | 125.72K | 104.22K | 89.13K | 18.27K |
| EBITDA | -9.27M | -8.74M | -21.37M | -2.01M | -1.54M | -5.47M | -7.80M | -3.91M | -2.60M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,470.36% | 0.00% | -5,470.36% | 0.00% |
| Operating Income | -9.38M | -8.85M | -20.37M | -2.05M | -1.56M | 15.32M | 10.17M | 15.32M | -2.60M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,470.36% | 0.00% | -5,470.36% | 0.00% |
| Total Other Income/Expenses | 714.32K | -123.79K | -1.09M | -425.35K | 0.00 | 2.54M | -1.06M | 237.07K | -19.30K |
| Income Before Tax | -8.66M | -9.38M | -21.46M | -2.10M | -1.56M | 15.32M | 10.17M | 15.32M | -2.62M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,470.36% | 0.00% | -5,470.36% | 0.00% |
| Income Tax Expense | 22.38K | -104.04K | -12.94M | -331.31K | 1.55M | -161.14K | -1.17M | 147.94K | -1.00 |
| Net Income | -8.69M | -9.28M | -8.52M | -1.76M | -1.56M | 15.32M | 10.17M | 15.32M | -2.62M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,470.36% | 0.00% | -5,470.36% | 0.00% |
| EPS | -9.64 | -22.97 | -322.49 | -88.10 | -440.29 | 7.10K | 5.45K | 10.08K | -2.11K |
| EPS Diluted | -9.64 | -22.97 | -322.49 | -88.10 | -440.29 | 7.10K | 5.45K | 10.08K | -2.11K |
| Weighted Avg Shares Out | 900.92K | 403.88K | 26.42K | 20.02K | 3.54K | 2.16K | 1.87K | 1.52K | 1.24K |
| Weighted Avg Shares Out (Dil) | 901.10K | 403.88K | 26.42K | 20.02K | 3.54K | 2.16K | 1.87K | 1.52K | 1.24K |
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024
ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter...
Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced that its Chief Executive Officer, Michael Myers, and...
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results
Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome to Include International Sites Announced Plans to Initiate Clinical Study in Peeling Skin Syndrome Continues to Evaluate M&A Opportunities in...
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New Zealand Company actively evaluating opening additional clinical sites in other countries ASHBURN, Va., Aug. 06, 2024 (GLOBE...
Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its second quarter...
Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the...
Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into late 2025 ASHBURN, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter...
Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript
Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports